Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 15, 2023 - Issue
Submit an article Journal homepage
106
Views
0
CrossRef citations to date
0
Altmetric
LETTER

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]

Slamet Wardoyo1 Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, IndonesiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3936-1893
ORCID Icon,
Muhammad Arief Fadillah2 Department of Medical Laboratory Technology, Poltekkes Kemenkes Banten, Tangerang, Indonesia
&
Hamtini2 Department of Medical Laboratory Technology, Poltekkes Kemenkes Banten, Tangerang, Indonesia
Pages 953-954 | Received 10 Dec 2023, Accepted 18 Dec 2023, Published online: 18 Dec 2023

References

  • Hu W, Wang L, Luo J, Zhang J, Li N. The potent novel CDK4/6 inhibitor TQB3616 in hormone receptor positive breast cancer: preclinical characterization with in vitro and human tumor xenograft models. Breast Cancer Targets Ther. 2023;15:899–912. doi:10.2147/BCTT.S434973
  • Zhang S, Xu Q, Sun W, Zhou J, Zhou J. Immunomodulatory effects of CDK4/6 inhibitors. Biochim Biophys Acta. 2023;1878:188912.
  • Zhaobing X, Lihong H, Yingchun L, et al. Preclinical evaluation of TQB3616, a highly potent and selective small-molecule CDK4/6 inhibitor. Cancer Res. 2018;78(13_Supplement):5778. doi:10.1158/1538-7445.AM2018-5778

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.